Last reviewed · How we verify

Estring Vaginal Product — Competitive Intelligence Brief

Estring Vaginal Product (Estring Vaginal Product) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen replacement therapy (vaginal). Area: Gynecology / Menopause.

marketed Estrogen replacement therapy (vaginal) Estrogen receptor (ER-α and ER-β) Gynecology / Menopause Small molecule Live · refreshed every 30 min

Target snapshot

Estring Vaginal Product (Estring Vaginal Product) — University of California, Irvine. Estring is a vaginal ring that releases estradiol directly into vaginal tissue to treat menopausal vaginal atrophy and related symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Estring Vaginal Product TARGET Estring Vaginal Product University of California, Irvine marketed Estrogen replacement therapy (vaginal) Estrogen receptor (ER-α and ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen replacement therapy (vaginal) class)

  1. University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estring Vaginal Product — Competitive Intelligence Brief. https://druglandscape.com/ci/estring-vaginal-product. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: